FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN¹

21 CFR Section	No. of Recordkeepers	Annual Frequency per Recordkeeping	Total Annual Records	Hours per Record	Total Hours
179.25(e), large processors	3	300	900	1	900
179.25(e), small processors	4	30	120	1	120
Total					1,020

¹There are no capital costs or operating and maintenance costs associated with this collection of information.

FDA bases its estimate of burden for the recordkeeping provisions of §179.25(e) on the agency's experience regulating the safe use of radiation as a direct food additive. The number of firms who process food using irradiation is extremely limited. FDA estimates that there are 3 irradiation plants whose business is devoted primarily (i.e., approximately 100 percent) to irradiation of food and other agricultural products. Four other firms also irradiate small quantities of food. FDA estimates that this irradiation accounts for no more than 10 percent of the business for each of these firms. Therefore, the average estimated burden is based on: Three facilities devoting 100 percent of their business to food irradiation $(3 \times$ 300 hours = 900 hours for recordkeeping annually); four facilities devoting 10 percent of their business to food irradiation $(4 \times 30 \text{ hours} = 120 \text{ hours for}$ recordkeeping annually).

No burden has been estimated for the labeling requirements in § 179.21(b)(1) and (b)(2) and § 179.26(c) because the information to be disclosed is information that has been supplied by FDA. Under 5 CFR 1320.3(c)(2), the public disclosure of information originally supplied by the Federal Government to the recipient for the purpose of disclosure to the public is not a collection of information.

Dated: May 14, 2009.

Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

[FR Doc. E9–11931 Filed 5–20–09; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases Diabetes Mellitus Interagency Coordinating Committee; Notice of Meeting

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), on behalf of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Diabetes Mellitus Interagency Coordinating Committee (DMICC), is convening an ad hoc planning and evaluation meeting to provide a midcourse assessment of ongoing preclinical research efforts supported by the Special Statutory Funding Program for Type 1 Diabetes Research and to discuss possible future directions for these efforts.

Sessions of the meeting will be open to the public as indicated below, with attendance limited to space available. Certain sessions, during which confidential information will be discussed, will be closed to the public. Members of the public planning to attend the meeting must register online at: http://www.scgcorp.com/ Type1Diabetes09/registration.asp. This is not a meeting to solicit public comment. Therefore, members of the public are permitted to attend the open sessions as observers only. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contact Person listed below at least 10 days in advance of the meeting.

Name: Meeting on Pre-Clinical Research Supported by the Special Statutory Funding Program for Type 1 Diabetes Research.

Place: National Institutes of Health, Neuroscience Building, 6001 Executive Blvd., Conference Room C, Bethesda, MD 20852. Date: June 17, 2009. Open: 8 a.m. to 8:45 a.m. Agenda: Meeting introduction; overview of the Type 1 Diabetes—Rapid Access to Intervention Development

- (T1D–RAID) research program. *Closed:* 8:45 a.m. to 9:30 a.m.
- *Agenda:* Mid-course assessment of T1D–RAID.

Open: 9:30 a.m. to 10 a.m. Agenda: Overview of the Type 1 **Diabetes Preclinical Testing Program** (T1D-PTP)-Prevention or Reversal of Type 1 Diabetes in Rodent Models. *Closed:* 10 a.m. to 10:30 a.m. Agenda: Mid-course assessment of the T1D-PTP-Prevention or Reversal of Type 1 Diabetes in Rodent Models. *Open:* 10:45 a.m. to 11:15 a.m. Agenda: Overview of the T1D–PTP– Prevention or Reversal of Diabetic Complications in Rodent Models. *Closed:* 11:15 a.m. to 11:45 a.m. Agenda: Mid-course assessment of the T1D-PTP-Prevention or Reversal of **Diabetic Complications in Rodent**

Models.

Open: 12:30 p.m. to 1 p.m. *Agenda:* Overview of the Animal

- Models of Diabetic Complications
- Consortium (AMDCC) research program. *Closed:* 1 p.m. to 2 p.m.

Agenda: Mid-course assessment of the AMDCC.

Open: 2 p.m. to 2:30 p.m. *Agenda:* Overview of the Type 1

Diabetes Resource.

Closed: 2:30 p.m. to 3:15 p.m.

Agenda: Mid-course assessment of the Type 1 Diabetes Resource.

Open: 3:30 p.m. to 4 p.m.

Agenda: Overview of Beta Cell

Biology Consortium (BCBC).

Closed: 4 p.m. to 5 p.m.

Agenda: Mid-course assessment of the BCBC.

Contact Person: Julie Wallace, PhD, Health Science Policy Analyst, Office of Scientific Program and Policy Analysis, National Institute of Diabetes and Digestive and Kidney Diseases, 9000 Rockville Pike, Building 31, Room 9A05, Bethesda, MD 20892, (301) 496– 6623, wallaceja@niddk.nih.gov. *Name:* Meeting on Pre-Clinical Research Supported by the Special Statutory Funding Program for Type 1 Diabetes Research.

Place: National Institutes of Health, Neuroscience Building, 6001 Executive Blvd., Conference Room C, Bethesda, MD 20852.

Date: June 18, 2009.

Open: 8 a.m. to 8:30 a.m.

Agenda: Overview of the Cooperative Study Group for Autoimmune Disease Prevention (Prevention Centers) research program.

Closed: 8:30 a.m. to 9 a.m.

Agenda: Mid-course assessment of the Prevention Centers.

Open: 9 a.m. to 9:30 a.m.

Agenda: Overview of the

Immunobiology of Xenotransplantation Cooperative Research Program (IXCRP) research program.

Closed: 9:30 a.m. to 10:15 a.m.

Agenda: Mid-course assessment of the IXCRP.

Open: 10:30 a.m. to 11 a.m. *Agenda:* Overview of the NHP Transplantation Tolerance Cooperative Study Group (NHPCSG).

Closed: 11 a.m. to 12:15 p.m.

Agenda: Mid-course assessment of the NHPCSG; discussion of cross-cutting themes for strengthening the ongoing preclinical research portfolio.

Open: 12:30 p.m. to 1:30 p.m. *Agenda:* Discussion of future

opportunities for preclinical research. *Contact Person:* Julie Wallace, PhD,

Health Science Policy Analyst, Office of Scientific Program and Policy Analysis, National Institute of Diabetes and Digestive and Kidney Diseases, 9000 Rockville Pike, Building 31, Room 9A05, Bethesda, MD 20892, (301) 496– 6623, wallaceja@niddk.nih.gov.

Please Note: The NIH has instituted security measures to ensure the safety of NIH employees and property. Upon your arrival at the Neuroscience Building, enter through the main lobby where you will be greeted at the security guard's desk. Visitors who are not NIH employees will be required to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to have their bags searched in order to enter the building. You will then be issued a visitor badge. In estimating your travel time, please allow for these security measures, particularly if you are arriving in a group. Self-parking is available for a maximum of \$8 per day.

A registration link, information about the meeting, and the agenda are available online: http:// www3.niddk.nih.gov/fund/ otherType1Diabetes09/. Dated: May 12, 2009. Sanford Garfield, Executive Secretary, DMICC, Division of Diabetes, Endocrinology and Metabolic

Diseases, NIDDK, National Institutes of Health.

[FR Doc. E9–11698 Filed 5–20–09; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel, Mentored Career Development, Institutional Research Training & Pathways to Independence Reviews.

Date: June 5, 2009.

Time: 11 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892. (Telephone Conference Call)

Contact Person: Charles H. Washabaugh, PhD, Scientific Review Administrator, Review Branch, NIAMS/NIH, 6701 Democracy Blvd., Room 816, Bethesda, MD 20892, 301–451–4838, washabac@mail.nih.gov.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel, Building Interdisciplinary Research Team (BIRT) II RFA.

Date: June 12, 2009.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892. (Virtual Meeting)

Contact Person: Charles H. Washabaugh, EP Review Branch NIAMS, One Democracy Plaza, Suite 800, MSC 4872, 6701 Democracy Plaza, Bethesda, MD 20892–4872, 301–496– 9568, *washabac@mail.nih.gov.* *Name of Committee:* National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel, Competitive Revision Reviews.

Date: June 24, 2009.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

Contact Person: Michael L. Bloom, Ph.D., MBA, Scientific Review Administrator, EP Review Branch, NIH/NIAMS, One Democracy Plaza, Room 820, MSC 4872, 6701 Democracy Blvd., Bethesda, MD 20892– 4872, 301–594–4953, Michael Bloom@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: May 14, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–11831 Filed 5–20–09; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): A Creutzfeldt-Jakob Disease (CJD) Lookback Study: Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease, Funding Opportunity Announcement (FOA) CK09–002, Initial Review

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting. *Time and Date:* 12 p.m.–3 p.m., June 5,

2009 (Closed). *Place:* Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Maîters to be Discussed: The meeting will include the initial review, discussion, and evaluation of "A Creutzfeldt-Jakob Disease Lookback Study: Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease, FOA CK09–002."

Contact Person for More Information: Wendy Carr, Ph.D., CDC, 1600 Clifton Road, NE., Mailstop D60, Atlanta, GA 30333, Telephone: (404) 498–2276.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices